Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) had its target price raised by equities researchers at Credit Suisse Group from $61.00 to $66.00 in a research note issued to investors on Thursday. The brokerage presently has an “outperform” rating on the biopharmaceutical company’s stock. Credit Suisse Group’s price target would indicate a potential upside of 2.69% from the stock’s previous close.
Several other analysts also recently weighed in on the company. SunTrust Banks, Inc. restated a “buy” rating and issued a $80.00 price target on shares of Agios Pharmaceuticals in a research note on Wednesday, October 4th. J P Morgan Chase & Co restated a “buy” rating and issued a $76.00 price target on shares of Agios Pharmaceuticals in a research note on Monday, September 18th. Royal Bank Of Canada began coverage on Agios Pharmaceuticals in a research note on Thursday, September 14th. They issued an “outperform” rating and a $78.00 price target on the stock. ValuEngine upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Finally, Oppenheimer Holdings, Inc. restated an “outperform” rating and issued a $83.00 price target (up previously from $75.00) on shares of Agios Pharmaceuticals in a research note on Thursday, August 10th. Three analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Agios Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $75.70.
Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) earnings per share for the quarter, topping the consensus estimate of ($1.78) by $0.19. The company had revenue of $11.35 million for the quarter, compared to the consensus estimate of $10.85 million. Agios Pharmaceuticals had a negative return on equity of 68.15% and a negative net margin of 502.12%. The firm’s quarterly revenue was up 26.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.63) EPS.
ILLEGAL ACTIVITY WARNING: This piece was originally posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at https://www.com-unik.info/2017/11/02/credit-suisse-group-boosts-agios-pharmaceuticals-inc-agio-price-target-to-66-00.html.
In other Agios Pharmaceuticals news, Director Lewis Clayton Jr. Cantley sold 4,000 shares of the stock in a transaction on Wednesday, August 23rd. The stock was sold at an average price of $56.85, for a total transaction of $227,400.00. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Scott Biller sold 2,146 shares of the stock in a transaction on Friday, September 1st. The shares were sold at an average price of $61.99, for a total value of $133,030.54. Following the sale, the insider now owns 8,410 shares in the company, valued at $521,335.90. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 170,762 shares of company stock worth $11,630,086. Company insiders own 10.55% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. boosted its stake in shares of Agios Pharmaceuticals by 163.9% in the 1st quarter. Russell Investments Group Ltd. now owns 2,549 shares of the biopharmaceutical company’s stock worth $149,000 after buying an additional 1,583 shares during the last quarter. QS Investors LLC purchased a new position in shares of Agios Pharmaceuticals in the 2nd quarter worth $144,000. S&CO Inc. purchased a new position in shares of Agios Pharmaceuticals in the 3rd quarter worth $227,000. Cubist Systematic Strategies LLC boosted its stake in shares of Agios Pharmaceuticals by 1,041.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 3,423 shares of the biopharmaceutical company’s stock worth $176,000 after buying an additional 3,123 shares during the last quarter. Finally, Aperio Group LLC purchased a new position in shares of Agios Pharmaceuticals in the 2nd quarter worth $206,000. Hedge funds and other institutional investors own 93.46% of the company’s stock.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
What are top analysts saying about Agios Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Agios Pharmaceuticals Inc. and related companies.